REDMOND, Wash., June 1, 2026
SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate (ADC) BL-M14D1, demonstrating promising anti-tumor activity in patients with small-cell lung cancer (SCLC) and neuroendocrine carcinomas during an oral presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The study findings highlight the growing potential of next-generation ADCs to address one of the most aggressive and treatment-resistant forms of lung cancer. Among heavily pretreated patients with advanced disease, BL-M14D1 achieved a notable 62% confirmed objective response rate and a median progression-free survival of 7.2 months, reinforcing its potential as a future treatment option in a disease setting with limited therapeutic advances. Based on these results, SystImmune plans to advance the program into a global registrational study in first-line extensive-stage SCLC, marking a significant milestone in the development of precision oncology therapies targeting DLL3-positive tumors.
Phase 1 Trial Delivers Impressive Clinical Responses
The Phase 1 BL-M14D1-101 study evaluated the safety and efficacy of the investigational ADC in patients with advanced solid tumors, including 87 patients with small-cell lung cancer and 40 patients with neuroendocrine carcinoma. Most participants had received multiple prior therapies, reflecting a heavily pretreated population with substantial unmet medical need. Among SCLC patients treated at the selected 4.0 mg/kg dose, BL-M14D1 achieved a confirmed objective response rate of 62%, with 21 of 34 patients experiencing significant tumor shrinkage.
In addition to the strong response rate, patients achieved a median progression-free survival of 7.2 months, a particularly encouraging outcome given the aggressive nature of extensive-stage SCLC and the limited effectiveness of currently available therapies following disease progression. The findings suggest that BL-M14D1 may offer meaningful clinical benefit by delivering potent anti-cancer activity in a patient population where durable responses remain difficult to achieve.
DLL3-Targeted ADC Technology Advances Precision Oncology
Advertisement
BL-M14D1 is part of SystImmune’s expanding portfolio of next-generation antibody-drug conjugates built on its proprietary brengitecan platform, which utilizes a highly potent topoisomerase I inhibitor payload for targeted delivery to tumor cells. The therapy specifically targets DLL3 (Delta-like ligand 3), a protein highly expressed in small-cell lung cancer and neuroendocrine tumors but minimally expressed in normal tissues. By selectively binding DLL3-positive cancer cells, BL-M14D1 delivers its cytotoxic payload directly to tumors while limiting systemic exposure.
This targeted mechanism is designed to improve efficacy while reducing off-target toxicity, an important objective in modern precision oncology. The success of ADC technologies across multiple cancer types has fueled increasing interest in DLL3 as a promising therapeutic target, particularly in SCLC where treatment options remain limited despite decades of research. The encouraging results presented at ASCO further validate DLL3-directed strategies and strengthen confidence in the broader clinical potential of ADC-based therapeutics.
Manageable Safety Profile Supports Global Development Plans
In addition to its strong anti-tumor activity, BL-M14D1 demonstrated a generally manageable safety profile. The most common treatment-emergent adverse events were hematologic in nature, including neutropenia and related blood count abnormalities, which were largely manageable with standard supportive care measures. Investigators reported that adverse events infrequently resulted in dose reductions or serious complications. One case of Grade 3 interstitial lung disease was observed, and one treatment-related death was reported, findings that will continue to be closely monitored as development progresses.
Overall, the safety profile was considered consistent with other topoisomerase I-based ADCs, supporting further clinical evaluation. Encouraged by the combination of efficacy and tolerability, SystImmune plans to rapidly advance BL-M14D1 into global registrational studies targeting first-line extensive-stage SCLC. If future studies confirm the promising Phase 1 findings, the therapy could emerge as a transformative treatment option for patients with DLL3-positive lung cancers and further establish antibody-drug conjugates as a cornerstone of next-generation cancer care.
Source: SystImmune press release
